Coronavirus pandemic: daily updated research and data.
Read more

Our data on COVID-19 vaccinations is updated each morning (London time), with the most recent official numbers up to the previous day.

In our Data Explorer you can see our data on the cumulative number of COVID-19 vaccination doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). You can find charts with the number of people with at least 1 dose, and the number of people fully vaccinated, further down this page.

Open the Data Explorer in a new tab.

Select a group of countries at once: all European countries, 30 largest countries; EU; Americas; OECD.


The Our World in Data COVID vaccination data

To bring this pandemic to an end, a large share of the world needs to be immune to the virus. The safest way to achieve this is with a vaccine. Vaccines are a technology that humanity has often relied on in the past to bring down the death toll of infectious diseases.

Within less than 12 months after the beginning of the COVID-19 pandemic, several research teams rose to the challenge and developed vaccines that protect from SARS-CoV-2, the virus that causes COVID-19.

Now the challenge is to make these vaccines available to people around the world. It will be key that people in all countries — not just in rich countries — receive the required protection. To track this effort we at Our World in Data are building the international COVID-19 vaccination dataset that we make available on this page. It is updated each morning, with the most recent official numbers up to the previous day.

  • Open access: as with all of our data, we are making this dataset openly available, so that everyone can check and use the data that we bring together. You find the vaccination data in our daily-updated repository on GitHub.

Country-by-country data on COVID-19 vaccinations

This page has a number of charts on vaccination. In the box below you can select any country you are interested in — or several, if you want to compare countries.

All charts on this page will then show data for the countries that you selected.

None selected

How many COVID-19 vaccine doses are administered daily?

Daily number of COVID-19 vaccinations administered per 100 people

The following chart shows the daily number of COVID-19 vaccination doses administered per 100 people. This is shown as the rolling seven-day average. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).

Daily number of COVID-19 vaccinations administered

How many COVID-19 vaccination doses have been administered?

The following map and chart show the number of COVID-19 vaccination doses administered per 100 people within a given population. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime as several available COVID vaccines require multiple doses.

Total number of COVID-19 vaccinations administered

The following chart shows the total number of COVID-19 vaccination doses administered. Note that this is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).

What share of the population has received at least one dose of the COVID-19 vaccine?

The following chart shows the share of the total population that has received at least one dose of the COVID-19 vaccine. This may not equal the share that are fully vaccinated if the vaccine requires two doses. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.

Total number of people who have received at least one dose of the COVID-19 vaccine

The following chart shows the total number of people that have received at least one dose of the COVID-19 vaccine. This may not equal the number that are fully vaccinated if the vaccine requires two doses. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same.

What share of the population has been fully vaccinated against COVID-19?

The following chart shows the share of the total population that has been fully vaccinated against COVID-19. This represents the share that have received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.

This data is only available for countries which report the breakdown of doses administered by first and second doses.

Total number of people who have been fully vaccinated against COVID-19

The following chart shows the total number of people that have been fully vaccinated against COVID-19. This represents the number that have received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1.

This data is only available for countries which report the breakdown of doses administered by first and second doses.

Which vaccines have been administered in each country?

The following chart shows the cumulative number of doses administered, broken down by vaccine manufacturer.

This is only available for a select number of countries which report the necessary data.

Vaccination policies

This interactive chart maps government policies on COVID-19 vaccination. Note that this only tracks policies on the availability of vaccinations. It does not track the number of people who have been vaccinated.

Countries are grouped into six categories:

  • No availability
  • Availability for ONE of following: key workers/ clinically vulnerable groups / elderly groups
  • Availability for TWO of following: key workers/ clinically vulnerable groups / elderly groups
  • Availability for ALL of following: key workers/ clinically vulnerable groups / elderly groups
  • Availability for all three plus partial additional availability (select broad groups/ages)
  • Universal availability

Vaccination policy data is sourced from the Oxford Coronavirus Government Response Tracker

This data on vaccination policies is sourced from the Oxford Coronavirus Government Response Tracker (OxCGRT).

This resource is published by researchers at the Blavatnik School of Government at the University of Oxford: Thomas Hale, Anna Petherik, Beatriz Kira, Noam Angrist, Toby Phillips and Samuel Webster.

The tracker presents data collected from public sources by a team of over one hundred Oxford University students and staff from every part of the world.

The data presented here is taken directly from the OxCGRT project; Our World in Data do not track policy responses ourselves, and do not make additions to the tracker dataset.

These charts are regularly updated based on the latest version of the response tracker.

OxCGRT is an ongoing collation project of live data. If you see any inaccuracies in the underlying data, or for specific feedback on the analysis or another aspect of the project please contact OxCGRT team. See the tracker’s notes and guidance on data quality.

Attitudes to COVID-19 vaccinations

The Imperial College London YouGov Covid-19 Behaviour Tracker Data Hub gathers global insights on people’s behaviors in response to COVID-19. This survey covers public behaviors and attitudes ranging from mask-wearing to self-isolation, social distancing, symptoms and testing.

The following chart shows monthly data on public willingness to receive the COVID-19 vaccine.

Data represents the share of respondents that agree with the following statement: “If a COVID-19 vaccine were made available to me this week, I would definitely get it.” Respondents were presented with a 1 to 5 scale, ranging from “Strongly agree” (1) to “Strongly disagree” (5). We consider responses of 1 or 2 to be in agreement with the statement.

Vaccine development: vaccines approved for use and in clinical trials

The speed at which the first COVID-19 vaccines were developed was extraordinary. We have previously looked into the history of vaccine development. The measles vaccine was found relatively rapidly: it took only 10 years from the discovery of the pathogen to the development of the first vaccine. But for typhoid it took more than a century, and for some diseases for which we’ve known the pathogens for more than a century (like malaria) we still haven’t found an effective vaccine.

The development of a vaccine against COVID-19 has been much faster than the development of any other vaccine. Within less than a year several successful vaccines have already been announced and were approved for use in some countries. 

The hope is that even more manufacturers develop vaccines for COVID-19. This will be important because eventually a very large share of the world population needs to receive a COVID-19 vaccine.

We are on the way to several vaccines against COVID-19 – vaccine trackers monitor the progress:

Several institutions maintain websites on which they list COVID-19 candidate vaccines that are currently being developed:

Source information country by country

You can download the full dataset alongside the detailed source descriptions on GitHub.

Note that other countries may have also started vaccination campaigns—we’ll add them to our maps and charts as soon as numbers are verifiable based on public official sources.

We do not include participants in the vaccine arm of clinical trials, as this data is not available for many of the hundreds of trials currently taking place.

The population estimates we use to calculate per-capita metrics are all based on the last revision of the United Nations World Population Prospects. The exact values can be viewed in our GitHub repository.

LocationSourceLast observation dateVaccines
AlbaniaMinistry of HealthFeb. 25, 2021Pfizer/BioNTech
AlgeriaMinistry of HealthFeb. 19, 2021Sputnik V
AndorraGovernment of AndorraFeb. 24, 2021Pfizer/BioNTech
AnguillaMinistry of HealthFeb. 14, 2021Oxford/AstraZeneca
ArgentinaMinistry of HealthFeb. 27, 2021Sputnik V
AustraliaGovernment of Australia via covidlive.com.auFeb. 27, 2021Pfizer/BioNTech
AustriaMinistry of HealthFeb. 26, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
AzerbaijanGovernment of AzerbaijanFeb. 6, 2021Oxford/AstraZeneca, Sputnik V
BahrainMinistry of HealthFeb. 27, 2021Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
BangladeshDirectorate General of Health ServicesFeb. 27, 2021Oxford/AstraZeneca
BarbadosMinistry of HealthFeb. 25, 2021Oxford/AstraZeneca
BelarusMinistry of HealthFeb. 18, 2021Sputnik V
BelgiumSciensanoFeb. 26, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
BermudaGovernment of BermudaFeb. 22, 2021Pfizer/BioNTech
BoliviaMinistry of HealthFeb. 11, 2021Sputnik V
BrazilRegional governments via Coronavirus BrasilFeb. 27, 2021Oxford/AstraZeneca, Sinovac
BulgariaMinistry of HealthFeb. 27, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
CambodiaMinistry of HealthFeb. 25, 2021Sinopharm/Beijing
CanadaGovernment of CanadaFeb. 26, 2021Moderna, Pfizer/BioNTech
Cayman IslandsCayman Islands GovernmentFeb. 25, 2021Pfizer/BioNTech
ChileDepartment of Statistics and Health InformationFeb. 27, 2021Pfizer/BioNTech, Sinovac
ChinaNational Health CommissionFeb. 9, 2021Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac
ColombiaMinistry of HealthFeb. 27, 2021Pfizer/BioNTech
Costa RicaNational Health CommissionFeb. 22, 2021Pfizer/BioNTech
CroatiaMinistry of HealthFeb. 25, 2021Pfizer/BioNTech
CyprusGovernment of CyprusFeb. 26, 2021Pfizer/BioNTech
CzechiaMinistry of HealthFeb. 27, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
DenmarkStatens Serum InstitutFeb. 26, 2021Moderna, Pfizer/BioNTech
Dominican RepublicMinistry of Public HealthFeb. 24, 2021Oxford/AstraZeneca
EcuadorGovernment of Ecuador via EcuacovidFeb. 24, 2021Pfizer/BioNTech
EgyptMinistry of HealthJan. 30, 2021Sinopharm/Beijing
El SalvadorMinistry of HealthFeb. 22, 2021Oxford/AstraZeneca
EnglandGovernment of the United KingdomFeb. 26, 2021Oxford/AstraZeneca, Pfizer/BioNTech
EstoniaNational Health BoardFeb. 27, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Faeroe IslandsGovernment of the Faeroe IslandsFeb. 24, 2021Pfizer/BioNTech
Falkland IslandsGovernment of the Falkland IslandsFeb. 15, 2021Oxford/AstraZeneca
FinlandFinnish Institute for Health and WelfareFeb. 27, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
FrancePublic Health FranceFeb. 26, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
GermanyRobert Koch InstitutFeb. 26, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
GibraltarGovernment of GibraltarFeb. 26, 2021Pfizer/BioNTech
GreeceMinistry of HealthFeb. 27, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
GreenlandGovernment of GreenlandJan. 27, 2021Pfizer/BioNTech
GuernseyGovernment of GuernseyFeb. 23, 2021Pfizer/BioNTech
GuyanaMinistry of HealthFeb. 22, 2021Oxford/AstraZeneca
HungaryGovernment of HungaryFeb. 26, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
IcelandDirectorate of HealthFeb. 26, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
IndiaMinistry of HealthFeb. 27, 2021Covaxin, Oxford/AstraZeneca
IndonesiaMinistry of HealthFeb. 27, 2021Sinovac
IranGovernment of IranFeb. 17, 2021Sputnik V
IrelandHeath Service ExecutiveFeb. 24, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Isle of ManIsle of Man GovernmentFeb. 27, 2021Oxford/AstraZeneca, Pfizer/BioNTech
IsraelGovernment of IsraelFeb. 27, 2021Moderna, Pfizer/BioNTech
ItalyExtraordinary commissioner for the Covid-19 emergencyFeb. 27, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
JapanMinistry of Health, Labour and WelfareFeb. 26, 2021Pfizer/BioNTech
JerseyGovernment of JerseyFeb. 21, 2021Oxford/AstraZeneca, Pfizer/BioNTech
KazakhstanGovernment of KazakhstanFeb. 24, 2021Sputnik V
KuwaitMinistry of HealthFeb. 15, 2021Pfizer/BioNTech
LatviaNational Health ServiceFeb. 27, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
LebanonGovernment of LebanonFeb. 27, 2021Pfizer/BioNTech
LiechtensteinFederal Office of Public HealthFeb. 24, 2021Moderna, Pfizer/BioNTech
LithuaniaMinistry of HealthFeb. 27, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
LuxembourgGovernment of LuxembourgFeb. 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
MacaoGovernment of MacaoFeb. 18, 2021Sinopharm/Beijing
MaldivesPresidency of the MaldivesFeb. 27, 2021Oxford/AstraZeneca
MaltaCOVID-19 Malta Public Health Response TeamFeb. 26, 2021Pfizer/BioNTech
MauritiusNational Communication Committee on COVID-19Feb. 17, 2021Oxford/AstraZeneca
MexicoSecretary of HealthFeb. 27, 2021Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
MonacoNational CouncilJan. 18, 2021Pfizer/BioNTech
MontenegroGovernment of MontenegroFeb. 26, 2021Sputnik V
MoroccoMinistry of HealthFeb. 27, 2021Oxford/AstraZeneca, Sinopharm/Beijing
MyanmarMinistry of HealthFeb. 2, 2021Oxford/AstraZeneca
NepalGovernment of NepalFeb. 20, 2021Oxford/AstraZeneca
NetherlandsNational Institute for Public Health and the EnvironmentFeb. 26, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
New ZealandMinistry of HealthFeb. 24, 2021Pfizer/BioNTech
Northern CyprusMinistry of HealthJan. 22, 2021Pfizer/BioNTech, Sinovac
Northern IrelandGovernment of the United KingdomFeb. 26, 2021Oxford/AstraZeneca, Pfizer/BioNTech
NorwayNorwegian Institute of Public HealthFeb. 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
OmanMinistry of HealthFeb. 23, 2021Oxford/AstraZeneca, Pfizer/BioNTech
PakistanNational Command and Operation CentreFeb. 21, 2021Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
PanamaMinistry of HealthFeb. 25, 2021Pfizer/BioNTech
ParaguayGovernment of ParaguayFeb. 25, 2021Sputnik V
PeruMinistry of HealthFeb. 26, 2021Sinopharm/Beijing
PolandMinistry of HealthFeb. 26, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
PortugalGeneral Directorate of Health via Data Science for Social GoodFeb. 27, 2021Moderna, Pfizer/BioNTech
QatarNational Strategic Group on COVID-19Feb. 18, 2021Pfizer/BioNTech
RomaniaGovernment of RomaniaFeb. 27, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
RussiaRussian Direct Investment FundFeb. 10, 2021Sputnik V
Saint HelenaGovernment of Saint HelenaFeb. 3, 2021Oxford/AstraZeneca
Saudi ArabiaSaudi Health CouncilFeb. 26, 2021Pfizer/BioNTech
ScotlandGovernment of the United KingdomFeb. 26, 2021Oxford/AstraZeneca, Pfizer/BioNTech
SenegalMinistry of HealthFeb. 26, 2021Sinopharm/Beijing
SerbiaGovernment of SerbiaFeb. 27, 2021Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
SeychellesExtended Programme for ImmunisationFeb. 25, 2021Oxford/AstraZeneca, Sinopharm/Beijing
SingaporeMinistry of HealthFeb. 18, 2021Pfizer/BioNTech
SlovakiaMinistry of HealthFeb. 26, 2021Pfizer/BioNTech
SloveniaNational Institute of Public Health, via SledilnikFeb. 26, 2021Oxford/AstraZeneca, Pfizer/BioNTech
South AfricaMinistry of HealthFeb. 27, 2021Johnson&Johnson
South KoreaKorea Centers for Disease Control and PreventionFeb. 27, 2021Oxford/AstraZeneca
SpainMinistry of HealthFeb. 25, 2021Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Sri LankaMinistry of HealthFeb. 26, 2021Oxford/AstraZeneca
SwedenPublic Health Agency of SwedenFeb. 26, 2021Oxford/AstraZeneca, Pfizer/BioNTech
SwitzerlandFederal Office of Public HealthFeb. 24, 2021Moderna, Pfizer/BioNTech
Trinidad and TobagoMinistry of HealthFeb. 22, 2021Oxford/AstraZeneca
TurkeyCOVID-19 Vaccine Information PlatformFeb. 27, 2021Sinovac
Turks and Caicos IslandsMinistry of HealthFeb. 8, 2021Pfizer/BioNTech
UkraineMinistry of HealthFeb. 26, 2021Oxford/AstraZeneca
United Arab EmiratesNational Emergency Crisis and Disaster Management AuthorityFeb. 27, 2021Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V
United KingdomGovernment of the United KingdomFeb. 26, 2021Oxford/AstraZeneca, Pfizer/BioNTech
United StatesCenters for Disease Control and PreventionFeb. 27, 2021Moderna, Pfizer/BioNTech
VenezuelaGovernment of VenezuelaFeb. 22, 2021Sputnik V
WalesGovernment of the United KingdomFeb. 26, 2021Oxford/AstraZeneca, Pfizer/BioNTech
ZimbabweMinistry of HealthFeb. 27, 2021Sinopharm/Beijing

Sign up for regular updates from Our World in Data


→ If you want to keep up-to-date with on our work on COVID-19, and the many other topics we cover you can sign up to our newsletter.